Longjin Pharmaceutical(002750)

Search documents
退市新规显威 首个年报季精准出清经营风险公司
Huan Qiu Wang· 2025-04-30 01:57
Group 1 - The implementation of new delisting regulations has led to a significant number of companies on the main board facing delisting risk warnings due to net profit losses and revenues below 300 million yuan [1][3] - As of April 29, a total of 48 companies have triggered financial delisting indicators, primarily in the social services, machinery, and textile industries, indicating prolonged losses and ineffective business transformations [3] - The new regulations aim to accurately identify "shell companies" and accelerate the elimination of poor-performing firms, thereby directing capital towards stable and fundamentally sound enterprises [3][4] Group 2 - The revenue threshold for delisting has been raised from 100 million yuan to 300 million yuan, intensifying the elimination of "zombie companies" [4] - *ST Longjin serves as a typical case under the new regulations, having been suspended due to continuous losses and revenues below 300 million yuan, with its revenue hovering around 100 million yuan from 2022 to 2024 [4] - The synergy between the new delisting rules and the comprehensive registration system is becoming evident, ensuring the effective operation of the capital market's survival of the fittest mechanism [4]
退市新规后首个年报季 组合类财务退市指标“亮剑”显威
Shang Hai Zheng Quan Bao· 2025-04-29 20:02
Core Viewpoint - The newly revised financial delisting indicators have effectively identified a number of main board companies with net profit losses and revenue below 300 million yuan, highlighting their weak operational sustainability and leading to delisting risk warnings for some companies [1][4]. Group 1: Financial Delisting Indicators - A total of 48 main board companies have triggered the new financial delisting indicators as of April 29, with industries such as social services, machinery, and textiles being the most affected [1]. - The new rules have raised the revenue threshold for delisting from 100 million yuan to 300 million yuan, directly impacting companies like Aiai Precision Engineering, which has struggled with revenue below the new threshold [2][4]. Group 2: Company Performance and Risks - Aiai Precision Engineering has reported continuous revenue below 300 million yuan since its listing in 2017, with a net profit loss of 8.8461 million yuan in 2024 due to poor operational performance and asset impairment [2]. - Other companies such as Weitai, Xingguang Co., and Sitong Co. have also faced delisting warnings due to similar financial issues, indicating a broader trend among underperforming firms [2][4]. Group 3: Regulatory Impact - The new delisting regulations are expected to accelerate the elimination of "shell" companies, thereby improving the overall quality of listed companies on the main board [1][4]. - Companies like *ST Longjin have been warned of delisting due to continuous losses and revenue below 100 million yuan, reflecting the stringent enforcement of the new rules [4]. Group 4: Broader Market Implications - The tightening of delisting criteria is seen as a mechanism to redirect capital towards more stable and profitable companies, enhancing the overall market quality [5][6]. - The regulatory framework aims to create a balanced and orderly exit for underperforming companies, facilitating a shift of resources towards high-quality enterprises [5][6].
财达证券晨会纪要-20250429
Caida Securities· 2025-04-29 03:22
Summary of Key Points Core Viewpoints - The report highlights the ongoing trend of stock suspensions due to delisting risk warnings across multiple companies, indicating a potential downturn in market confidence and stability [2][3][4]. Company Listings - Several companies are scheduled for initial public offerings (IPOs) on April 29, 2025, including Tai Li Technology (301595) and Ze Run New Energy (301636), which may attract investor interest [1]. - The report notes the specific dates for various IPO-related activities, such as inquiry periods and fund unfreezing dates, which are crucial for market participants [1]. Stock Suspension Announcements - Numerous companies, including Guohua Network Security (000004) and Nanhua Biology (000504), have announced stock suspensions due to delisting risk warnings, reflecting a significant concern regarding their financial health [2][3]. - The report lists a total of 30 companies facing stock suspensions on April 29, 2025, due to various risk warnings, which may impact investor sentiment and trading volumes [2][3][4]. Special Suspensions - Companies like *ST Xu Lan (000040) and *ST Gong Zhi (000584) are highlighted for potential termination of listings, indicating severe financial distress and regulatory scrutiny [4][5]. - The report emphasizes the importance of monitoring these companies as their situations evolve, which could present both risks and opportunities for investors [4][5].
龙津药业(002750) - 2025 Q1 - 季度财报
2025-04-28 13:25
Financial Performance - The company's revenue for Q1 2025 was ¥5,901,760.59, a decrease of 77.64% compared to ¥26,388,422.34 in the same period last year[5] - The net profit attributable to shareholders was -¥4,079,872.65, showing an improvement of 9.17% from -¥4,491,776.72 year-on-year[5] - Total operating revenue for the current period is 5,901,760.59, a decrease of 77.7% compared to 26,388,422.34 in the previous period[19] - Net profit for the current period is -4,890,695.58, an improvement from -5,566,204.56 in the previous period[20] - Basic and diluted earnings per share for the current period are both -0.0102, slightly improved from -0.0112 in the previous period[21] Cash Flow and Assets - The net cash flow from operating activities was -¥12,849,141.89, a decline of 169.70% compared to -¥4,764,302.80 in the previous year[5] - Operating cash flow for the current period is -12,849,141.89, worsening from -4,764,302.80 in the previous period[22] - The company's cash and cash equivalents decreased from 261,742,130.25 CNY to 50,854,157.95 CNY, a decline of approximately 80.6%[15][16] - Cash and cash equivalents at the end of the period are 50,854,097.38, down from 129,653,249.19 in the previous period[23] - Total current assets decreased from 338,177,284.73 CNY to 311,106,917.55 CNY, a reduction of about 8%[16] - The total liabilities decreased from 80,185,043.61 CNY to 69,958,735.88 CNY, a decrease of approximately 12.5%[17] - The company's total assets decreased from 574,398,586.84 CNY to 555,151,183.53 CNY, a decline of about 3.4%[17] Shareholder Information - The total number of common shareholders at the end of the reporting period is 29,091[11] - The largest shareholder, Kunming Qunxing Investment Co., Ltd., holds 39.40% of the shares, totaling 157,782,293 shares[11] Government Support and Subsidies - The company received government subsidies amounting to ¥846,338.40 during the reporting period[6] - Other income for the current period is 846,338.40, an increase from 677,867.89 in the previous period[20] Expenses and Costs - The company's sales expenses decreased by 83.84% to ¥2,796,905.35 due to the implementation of centralized procurement policies[9] - Total operating costs for the current period are 11,934,554.14, down 64.7% from 33,756,765.30 in the previous period[19] - Research and development expenses for the current period are 1,676,309.60, down from 1,992,368.82 in the previous period[19] Investment and Financial Assets - The company reported a significant increase in trading financial assets, which rose by 556.62% to ¥219,437,991.06[9] - The company’s investment income decreased by 95.55% to ¥29,110.89, attributed to cash management products not maturing[9] - Investment activities generated a net cash flow of -197,329,574.98, compared to -86,299,874.27 in the previous period[23] Risks and Challenges - The company has received a notice from the Shenzhen Stock Exchange regarding the potential termination of its stock listing due to negative profits and revenue below ¥300 million[4] - The core product, Longjin® injection of Lampflower extract, is expected to face risks of declining sales and revenue due to the national centralized procurement policy starting in April 2025[14] Asset Changes - The company's retained earnings decreased from 18,950,761.77 CNY to 14,870,889.12 CNY, a decline of approximately 21.4%[17] - The total equity attributable to the parent company decreased from 470,459,142.64 CNY to 464,319,475.03 CNY, a reduction of about 1.4%[17] - The company's intangible assets increased by 51.35% to ¥50,465,817.98 due to new drug production approvals[9]
ST龙津2024年盈利能力回升但仍面临经营压力
Zheng Quan Zhi Xing· 2025-04-27 22:40
Operating Overview - The total operating revenue of ST Longjin (002750) for 2024 was 66.48 million yuan, a year-on-year decrease of 23.25% [2] - The net profit attributable to shareholders was -41.44 million yuan, an increase of 41.58% year-on-year; the net profit after deducting non-recurring gains and losses was -50.46 million yuan, up 37.78% year-on-year [2] - Despite poor annual performance, the fourth quarter showed improvement with total operating revenue of 19.87 million yuan, a year-on-year increase of 27.65% [2] Profitability Analysis - The company's profitability improved in 2024, with a gross margin of 64.25%, an increase of 5.53% year-on-year [3] - The net profit margin was -70.66%, an increase of 27.36% year-on-year, indicating that the company remains in a loss position [3] Cost and Expense Analysis - Total sales, management, and financial expenses amounted to 66.58 million yuan, accounting for 100.15% of revenue, a decrease of 7.73% year-on-year [4] - The reduction in sales expenses was primarily due to the implementation of centralized procurement price linkage policies in non-centralized procurement provinces [4] Cash Flow Situation - The operating cash flow per share was -0.09 yuan, an increase of 12.8% year-on-year, indicating some improvement [5] - However, the average operating cash flow over the past three years relative to current liabilities was -78.8%, suggesting ongoing concerns regarding cash flow [5] Asset and Liability Situation - The company's cash and cash equivalents amounted to 262 million yuan, a year-on-year increase of 24.2%, indicating a healthy cash position [6] - Accounts receivable decreased by 27.86% year-on-year to 8.75 million yuan, reflecting improved collection [6] Development Prospects and Risks - The company has been deeply involved in the pharmaceutical manufacturing industry for many years, holding nearly 40 domestic and foreign invention patents [7] - However, the product structure remains single, with revenues from other chemical generic drugs being relatively small [7] - The company faces multiple risks, including industry policy changes, research and development innovation, management, and safety and environmental protection [7] Summary - Overall, ST Longjin showed some recovery in profitability in 2024, but the overall operating condition remains under significant pressure [8] - The company needs to further optimize its product structure, enhance market competitiveness, and strengthen cash flow management and risk prevention for sustainable development [8]
300117,终止上市!002750,触及退市


Zheng Quan Shi Bao· 2025-04-26 12:44
Group 1 - *ST嘉寓 has received a decision from the Shenzhen Stock Exchange to terminate its stock listing due to its stock price being below 1 yuan for 20 consecutive trading days from March 4 to March 31, 2025 [2][3] - The stock of *ST嘉寓 will be delisted within fifteen trading days after the termination decision, and it will not enter a delisting transition period [2][3] - As of April 1, 2024, *ST嘉寓's stock was suspended from trading, with a closing price of 0.43 yuan per share and a total market value of 308 million yuan [2] Group 2 - In 2024, *ST嘉寓 reported an operating income of 482.18 million yuan, a decrease of 59.94% year-on-year, and a net loss attributable to shareholders of 356.47 million yuan [3][4] - By the end of 2024, the net assets attributable to shareholders were -1.96 billion yuan, reflecting a 32.16% decline compared to the end of 2023 [4] - The total assets of *ST嘉寓 decreased by 63.99% year-on-year, amounting to approximately 902.61 million yuan at the end of 2024 [4] Group 3 - *ST龙津 has received a notice from the Shenzhen Stock Exchange regarding the potential termination of its stock listing due to negative net profit and operating income below 1 billion yuan for the fiscal year 2023 [5][6] - The company’s stock was suspended from trading on April 25, 2024, with a closing price of 1.13 yuan per share and a total market value of 453 million yuan [7] - For the fiscal year 2024, *ST龙津 reported an operating income of 66.48 million yuan, a decrease of 23.25% year-on-year, and a net loss of 41.44 million yuan [8][9]
*ST龙津(002750) - 关于收到终止上市事先告知书的公告
2025-04-25 15:43
股票代码:002750 股票简称:*ST 龙津 公告编号:2025-046 昆明龙津药业股份有限公司 关于收到终止上市事先告知书的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整,没有虚 假记载、误导性陈述或重大遗漏。 二、风险提示 1 根据《深圳证券交易所股票上市规则》及《关于退市公司进入退市板块挂牌 转让的实施办法》等有关规定,如果深圳证券交易所最终决定公司股票终止上市, 公司股票将转入全国股转公司代为管理的退市板块挂牌转让,涉及具体事项公司 将另行公告。 公司郑重提醒广大投资者,《证券时报》和深圳证券交易所网站 (www.szse.cn)为公司选定的信息披露媒体,公司所有信息均以在上述媒体披 露的信息为准。请广大投资者理性投资,注意风险。 三、备查文件 一、《终止上市事先告知书》的具体内容 昆明龙津药业股份有限公司(以下简称"公司")2025 年 4 月 25 日收到深 圳证券交易所送达的《终止上市事先告知书》(公司部函[2025]第 193 号),具 体内容如下: "昆明龙津药业股份有限公司: 2024 年 5 月 6 日,因你公司 2023 年度经审计的净利润为负值且营业收入低 于 1 ...
*ST龙津(002750) - 内部控制审计报告
2025-04-24 17:44
众环审字(2025)1600306号 昆明龙津药业股份有限公司 内部控制审计报告 按照《企业内部控制审计指引》及中国注册会计师执业准则的相关要求,我们审计了昆明 龙津药业股份有限公司(以下简称"龙津药业")2024年12月 31 日的财务报告内部控制的有效 性。 一、龙津药业对内部控制的责任 按照《企业内部控制基本规范》、《企业内部控制应用指引》、《企业内部控制评价指引》的 规定,建立健全和有效实施内部控制,并评价其有效性是龙津药业董事会的责任。 二、注册会计师的责任 我们的责任是在实施审计工作的基础上,对财务报告内部控制的有效性发表审计意见,并 对注意到的非财务报告内部控制的重大缺陷进行披露。 三、内部控制的固有局限性 内部控制具有固有局限性,存在不能防止和发现错报的可能性。此外,由于情况的变化可 能导致内部控制变得不恰当,或对控制政策和程序遵循的程度降低,根据内部控制审计结果推 测未来内部控制的有效性具有一定风险。 四、财务报告内部控制审计意见 内部容制度计报告 众环审字(2025)1600306 号 昆明龙津药业股份有限公司全体股东: 让明该审计报告是否由具有权业许 您可使用手机"扫一扫"或进入"注册会 ...
*ST龙津(002750) - 2024年年度审计报告
2025-04-24 17:44
昆明龙津药业股份有限公司 审计报告 众环审字(2025)1600305号 目 录 | | 起始页码 | | --- | --- | | 审计报告 | 1 | | 财务报表 | | | 合并资产负债表 | | | 合并利润表 | 3 | | 合并现金流量表 | 4 | | 合并股东权益变动表 | 5 | | 资产负债表 | 7 | | 利润表 | 9 | | 现金流量表 | 10 | | 股东权益变动表 | 11 | | 财务报表附注 | 13 | 审计报告 众环审字(2025)1600305 号 昆明龙津药业股份有限公司全体股东: 一、审计意见 我们审计了昆明龙津药业股份有限公司(以下简称"龙津药业")财务报表,包括 2024年 12 月 31 日的合并及公司资产负债表,2024年度的合并及公司利润表、合并及公司现金流量, 表、合并及公司股东权益变动表以及相关财务报表附注。 我们认为,后附的财务报表在所有重大方面按照企业会计准则的规定编制,公允反映了 龙津药业 2024年 12月 31 日合并及公司的财务状况以及 2024年度合并及公司的经营成果和 现金流量。 二、形成审计意见的基础 我们按照中国注册会计师审 ...
*ST龙津(002750) - 年度关联方资金占用专项审计报告
2025-04-24 17:44
关于昆明龙津药业股份有限公司 非经营性资金占用及 其他关联资金往来情况 汇总表的专项审核报告 众环专字(2025)1600049号 目 起始页码 专项审核报告 汇总表 非经营性资金占用及其他关联资金往来的情况汇总表 1 1 干昆明龙津药业股份有限公司 也关联资金在采 SEDV 众环专字(2025)1600049 号 昆明龙津药业股份有限公司全体股东: 我们接受委托,在审计了昆明龙津药业股份有限公司(以下简称"龙津药业")2024年 12月 31 日合并及公司的资产负债表,2024年度合并及公司的利润表、合并及公司的现金流 量表和合并及公司的股东权益变动表以及财务报表附注的基础上,对后附的《上市公司 2024 年度非经营性资金占用及其他关联资金往来的情况汇总表》(以下简称"汇总表")进行了专 项审核。按照中国证券监督管理委员会印发的《上市公司监管指引第 8号 -- 上市公司资金 往来、对外担保的监管要求》的规定,编制和披露汇总表、提供真实、合法、完整的审核证 据是龙津药业管理层的责任,我们的责任是在执行审核工作的基础上对汇总表发表专项审核 意见。 我们按照中国注册会计师审计准则的相关规定执行了审核工作。中国注册 ...